Natco's Affordable Semaglutide Shakes India's Drug Market at INR 1,290

Natco Pharma has just shaken up the India’s diabetes drug market with its launch of semaglutide at just INR 1,290 a month, making high-end diabetes treatment far more affordable for millions.

This move comes on the very day semaglutide patent expires in India, allowing generic makers to enter the market with lower-priced options.

The Hyderabad based company’s new semaglutide offering is priced significantly below branded alternatives, undercutting existing products by a wide margin. Multidose vials start at INR 1,290 and go up to around INR 1,750 depending on strength, while future pen formats could be priced lower than current premium options.

Also Read: Ozempic Patent Expiry Drives Surge in Pharma Stocks Ahead of Launch

Semaglutide is a GLP-1 therapy used to manage type-2 diabetes and weight loss, and has been one of the most sought after drugs in recent years due to strong clinical benefits. With the patent expiry, Natco’s low-cost semaglutide aims to put this therapy within reach of a much broader segment of patients who previously saw branded versions as too expensive.

Industry watchers say this launch will trigger a price battle in India’s fast growing GLP-1 market. Several other Indian drugmakers like Sun Pharma and Dr. Reddy’s are also poised to introduce their own semaglutide generics soon, intensifying competition and pushing prices down further.

The move could radically change how diabetes care is delivered in India, especially for people who need ongoing weekly injections but have struggled with steep costs. Lower pricing could also expand the use of semaglutide for weight management, a growing concern in a country with a rising rate of obesity and metabolic health issues.

Natco’s tentative first mover advantage in the generic semaglutide space may also influence other major players to rethink their pricing strategies. Analysts believe that as more generics launch, diabetes treatment costs in India could fall sharply, improving access and adherence for patients nationwide.